The companies signed an agreement to co-develop & commercialize Verge’s VRG50635 for the treatment of sporadic and familial forms of ALS across EU, Central & South America, Southeast Asia & Japan
Under the terms of the agreement, Ferrer received the exclusive rights to co-develop & commercialize VRG50635 across multiple regions outside the US whereas Verge retains all the development and commercialization rights for all uses in the US & all countries outside the agreement
VRG50635 is a small molecule inhibitor of PIKfyve (developed using an AI-enabled platform) & is currently being evaluated in a P-I PoC study across Canada & various European Countries for safety, efficacy & pharmacological dose-response
Ref: Globenewswire | Image: Verge Genomics
Related News:- Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
